The invention relates to methods for producing botanical extracts comprising cannabinoids and terpenes using cold extraction with highly polyunsaturated lipid solvents. These methods allow for the extraction of cannabinoids and terpenes while leaving behind impurities that are commonly found in organic solvent extraction methods.

The present disclosure provides methods for preparing polyunsaturated hydrocarbons, such as E,E-farnesol, farnesyl acetate and squalene, by base catalyzed addition of a dialkylamine to a 3-methylene-1-alkene, such as farnesene. The present disclosure also provides compositions including one more farnesene derivatives prepared using the disclosed methods.

The present disclosure provides methods for preparing polyunsaturated hydrocarbons, such as E,E-farnesol, farnesyl acetate and squalene, by base catalyzed addition of a dialkylamine to a 3-methylene-1-alkene, such as farnesene. The present disclosure also provides compositions including one more farnesene derivatives prepared using the disclosed methods.

The use of lycopene has been demonstrated to be effective in decreasing risk factors associated with cardiovascular disease, skin cancer and prostate cancer in mammals. Lycopene is difficult to solubilize in its native trans-lycopene form. Cis-lycopene, formed by applying thermal energy generated by excitation of polar molecules through microwave-assisted processing, appears in several isomeric forms. The cis isomers are effective in improving lycopene micellularization, bioaccessibility and mammalian absorption. The cis isomers are effective in improving vascular circulation of lycopene by way transport vesicle low density lipo-protein (LDL). Lycopene-based ingredients, end products, functional foods, medical foods and nutraceuticals, containing isomerized cis-lycopene can be used in place of ingredients with more naturally abundant trans-lycopene as phytonutrient, micronutrient and antioxidant delivery vehicles through dietary consumption to improve the outcomes of a variety of conditions, including hypertension, cardiovascular disease, skin cancer, prostate cancer, macular degeneration and related proinflammatory conditions.

The use of lycopene has been demonstrated to be effective in decreasing risk factors associated with cardiovascular disease, skin cancer and prostate cancer in mammals. Lycopene is difficult to solubilize in its native trans-lycopene form. Cis-lycopene, formed by applying thermal energy generated by excitation of polar molecules through microwave-assisted processing, appears in several isomeric forms. The cis isomers are effective in improving lycopene micellularization, bioaccessibility and mammalian absorption. The cis isomers are effective in improving vascular circulation of lycopene by way transport vesicle low density lipo-protein (LDL). Lycopene-based ingredients, end products, functional foods, medical foods and nutraceuticals, containing isomerized cis-lycopene can be used in place of ingredients with more naturally abundant trans-lycopene as phytonutrient, micronutrient and antioxidant delivery vehicles through dietary consumption to improve the outcomes of a variety of conditions, including hypertension, cardiovascular disease, skin cancer, prostate cancer, macular degeneration and related proinflammatory conditions.

Processes and systems for stabilization and subsequent hydrogenation of an immiscible olefin are described. In certain embodiments, the hydrogenation is conducted in a fixed bed reactor in presence of a hydrogenation catalyst.

Processes and systems for stabilization and subsequent hydrogenation of an immiscible olefin are described. In certain embodiments, the hydrogenation is conducted in a fixed bed reactor in presence of a hydrogenation catalyst.

Processes and systems for stabilization and subsequent hydrogenation of an immiscible olefin are described. In certain embodiments, the hydrogenation is conducted in a fixed bed reactor in presence of a hydrogenation catalyst.

The application relates to a process for the production of alpha-springene (formula (I)) and beta-springene (formula (II)) from geranyl geranyl acetate (formula (III)).

##STR00001##

The application relates to a process for the production of alpha-springene (formula (I)) and beta-springene (formula (II)) from geranyl geranyl acetate (formula (III)).

##STR00001##